戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 0 mg or 40 mg of hyoscine butylbromide or no spasmolytic.
2 ly, the five tested ITCs exerted significant spasmolytic activity (on rat distal colon), with PhPeITC
3 lalkyl isothiocyanates were tested for their spasmolytic, cytotoxic and antimicrobial activities.
4      Prior to the examination, 20-40 mg of a spasmolytic drug, hioscine-N-butylobromide (Buscolysin((
5 ared with control subjects, patients given a spasmolytic had odds of 6.49 for clinically adequate dis
6 refoil family factor 2 (TFF2), also known as spasmolytic peptide, is a low-molecular-weight protein t
7 estrogen-inducable gene pS2 (BCEI) and human spasmolytic polypeptide (hSP/SML1).
8                       The trefoil pancreatic spasmolytic polypeptide (PSP) was tested for growth acti
9                            Recombinant human spasmolytic polypeptide (rHSP) or rat intestinal trefoil
10  trefoil auto- and cross-induction, and both spasmolytic polypeptide (SP) and ITF stimulation of gast
11 r (ITF, 59 residues), pS2 (60 residues), and spasmolytic polypeptide (SP, 106 residues) form a small
12          Both intestinal metaplasia (IM) and spasmolytic polypeptide (TFF2/SP) expressing metaplasia
13                      Trefoil factor family 2/spasmolytic polypeptide and intrinsic factor dual-immuno
14 adenocarcinoma are intestinal metaplasia and spasmolytic polypeptide expressing metaplasia (SPEM), de
15 broblasts, loss of parietal and chief cells, spasmolytic polypeptide expressing metaplasia, and dyspl
16  family (pS2, intestinal trefoil factor, and spasmolytic polypeptide) are produced in the mammalian g
17 e described a trefoil factor family 2 (TFF2; spasmolytic polypeptide) expressing metaplasia (SPEM) as
18 refoil factor family 2 (TFF2), also known as spasmolytic polypeptide, is a member of the trefoil fami
19 ntified cellular and molecular mechanisms in spasmolytic polypeptide-expressing (pseudopyloric) metap
20               Intestinal metaplasia (IM) and spasmolytic polypeptide-expressing metaplasia (SPEM) are
21                                              Spasmolytic polypeptide-expressing metaplasia (SPEM) dev
22  differentiation factor that correlates with spasmolytic polypeptide-expressing metaplasia (SPEM) in
23                                    To induce spasmolytic polypeptide-expressing metaplasia (SPEM), am
24 velops in the context of parietal cell loss, spasmolytic polypeptide-expressing metaplasia (SPEM), an
25 emergence of a type of metaplasia designated spasmolytic polypeptide-expressing metaplasia (SPEM).
26 MBT1, were validated as specific markers for spasmolytic polypeptide-expressing metaplasia and intest
27                                 Induction of spasmolytic polypeptide-expressing metaplasia with DMP-7
28 yntic atrophy, mucous neck cell hyperplasia, spasmolytic polypeptide-expressing metaplasia, dysplasia
29 ucous cell lineage that stained positive for spasmolytic polypeptide.
30 with DMP-777 leads to the rapid emergence of spasmolytic polypeptide/trefoil factor family 2 (TFF2)-e

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。